Shares of Anika Therapeutics ANIK were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share fell 72.09% year over year to $0.12, which beat the estimate of ($0.01).
Revenue of $32,688,000 rose by 9.79% year over year, which missed the estimate of $33,500,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Anika Therapeutics hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Mar 04, 2021
Time: 05:00 PM
ET Webcast URL: http://public.viavid.com/player/index.php?id=143334
Technicals
Company's 52-week high was at $47.48
Company's 52-week low was at $22.01
Price action over last quarter: Up 12.48%
Company Profile
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company's product profile includes Orthobiologics, Dermal, Surgical and other of which Orthobiologics products generates maximum revenue to the company.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
